Top

Published in:

01-01-2015 | Special Feature

The Japanese Breast Cancer Society clinical practice guideline for epidemiology and prevention of breast cancer

Authors: Naruto Taira, Masami Arai, Masahiko Ikeda, Motoki Iwasaki, Hitoshi Okamura, Kiyoshi Takamatsu, Seiichiro Yamamoto, Shozo Ohsumi, Hirofumi Mukai

Published in: Breast Cancer | Issue 1/2015

Excerpt

The vital statistics of the Ministry of Health, Labour and Welfare show that the crude and age-adjusted death rates of patients with breast cancer increased consistently from the 1960s to 2011, but decreased in 2012. The number of deaths due to breast cancer in women was 12,529 in 2012. The crude death rate was 19.4 per 0.1 million population and ranked fifth highest, behind colon/rectum, lung, stomach, and pancreatic cancers in descending order. The age-adjusted death rate was 11.5 per 0.1 million population, which was second only to colon/rectum cancer and was followed by lung and stomach cancers. The age-specific death rate increased in a linear fashion under the age of 50 and slightly decreased until 80 years old. The age-adjusted death rate from breast cancer in Western countries is substantially greater than that in Japan, but has shown a tendency to decrease after reaching a peak around 1990, and thus the gap with Japan has been reduced [1]. …

Kawamura T, Sobue T. Comparison of breast cancer mortality in five countries:France, Italy, Japan, the UK and the USA from the WHO mortality database (1960–2000). Jpn J Clin Oncol. 2005;35:758–9.PubMedCrossRef

Katanoda K, Qiu D. Comparison of time trends in female breast cancer incidence (1973 1997) in East Asia, Europe and USA, from cancer incidence in five Continents, Vols IV VIII. Jpn J Clin Oncol. 2007;37:638–9.PubMedCrossRef

World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington DC: AICR; 2007.

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.PubMedCrossRef

Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, et al. Japan Public Health Center-based Prospective Study Group. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status-the Japan public health center-based prospective study. Int J Cancer. 2011;129:1214–24.PubMedCrossRef

Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V. Million Women Study collaborators. Height and cancer incidence in the Million Women Study:prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol. 2011;12:785–94.PubMedCentralPubMedCrossRef

White KK, Park SY, Kolonel LN, Henderson BE, Wilkens LR. Body size and breast cancer risk: the multiethnic cohort. Int J Cancer. 2012;131:E705–16.PubMedCrossRef

Sung J, Song YM, Lawlor DA, Smith GD, Ebrahim S. Height and site-specific cancer risk: a cohort study of a Korean adult population. Am J Epidemiol. 2009;170:53–64.PubMedCrossRef

Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15:36–47.PubMed

10.

Kawai M, Minami Y, Kuriyama S, Kakizaki M, Kakugawa Y, Nishino Y, et al. Reproductive factors, exogenous female hormone use and breast cancer risk in Japanese: the Miyagi cohort study. Cancer Causes Control. 2010;21:135–45.PubMedCrossRef

11.

Tamakoshi K, Yatsuya H, Wakai K, Suzuki S, Nishio K, Lin Y, et al. JACC Study Group. Impact of menstrual and reproductive factors on breast cancer risk in Japan: results of the JACC study. Cancer Sci. 2005;96:57–62.PubMedCrossRef

12.

Iwasaki M, Otani T, Inoue M, Sasazuki S, Tsugane S. Japan Public Health Center-based prospective study group. Role and impact of menstrual and reproductive factors on breast cancer risk in Japan. Eur J Cancer Prev. 2007;16:116–23.PubMedCrossRef

13.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breast feeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360:187–95.CrossRef

14.

Tokunaga M, Land CE, Yamamoto T, Asano M, Tokuoka S, Ezaki H, et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1980. Radiat Res. 1987;112:243–72.PubMedCrossRef

15.

Tokunaga M, Land CE, Tokuoka S, Nishimori I, Soda M, Akiba S. Incidence of female breast cancer among atomic bomb survivors, 1950–1985. Radiat Res. 1994;138:209–23.PubMedCrossRef

16.

Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Jr. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002;158:220–35.PubMedCrossRef

17.

Doody MM, Lonstein JE, Stovall M, Hacker DG, Luckyanov N, Land CE. Breast cancer mortality after diagnostic radiography: findings from the US scoliosis cohort study. Spine. 2000;25:2052–63 (Phila Pa 1976).PubMedCrossRef

18.

Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010;152:444–55.PubMedCentralPubMedCrossRef

19.

Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361:125–9.PubMedCrossRef

20.

Page DL, Dupont WD, Jensen RA. Papillary apocrine change of the breast: associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 1996;5:29–32.PubMed

21.

Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 1994;331:10–5.PubMedCrossRef

22.

Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312:146–51.PubMedCrossRef

23.

Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229–37.PubMedCrossRef

24.

Kabat GC, Jones JG, Olson N, Negassa A, Duggan C, Ginsberg M, et al. A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control. 2010;21:821–8.PubMedCentralPubMedCrossRef

25.

Ma L, Boyd NF. Atypical hyperplasia and breast cancer risk: a critique. Cancer Causes Control. 1992;3:517–25.PubMedCrossRef

26.

Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997;71:800–9.PubMedCrossRef

27.

Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. WHI investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684–92.PubMedCrossRef

28.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047–59.CrossRef

29.

Collins JA, Blake JM, Crosignani PG. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update. 2005;11:545–60.PubMedCrossRef

30.

Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update. 2005;11:561–73.PubMedCrossRef

31.

Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3 N cohort study. Breast Cancer Res Treat. 2008;107:103–11.PubMedCentralPubMedCrossRef

32.

Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13:476–86.PubMedCentralPubMedCrossRef

33.

Saeki T, Sano M, Komoike Y, Sonoo H, Honjyo H, Ochiai K, et al. No increase of breast cancer incidence in Japanese women who received hormone replacement therapy: overview of a case-control study of breast cancer risk in Japan. Int J Clin Oncol. 2008;13:8–11.PubMedCrossRef

34.

35.

Nagata C, Mizoue T, Tanaka K, Tsuji I, Wakai K, Inoue M, et al. Research group for the development and evaluation of cancer prevention strategies in Japan. Alcohol drinking and breast cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2007;37:568–74.PubMedCrossRef

36.

Suzuki R, Iwasaki M, Inoue M, Sasazuki S, Sawada N, Yamaji T, et al. Japan Public Health Center-Based Prospective Study Group. Alcohol consumption-associated breast cancer incidence and potential effect modifiers: the Japan public health center-based prospective study. Int J Cancer. 2010;127:685–95.PubMedCrossRef

37.

Kawai M, Minami Y, Kakizaki M, Kakugawa Y, Nishino Y, Fukao A, et al. Alcohol consumption and breast cancer risk in Japanese women: the Miyagi cohort study. Breast Cancer Res Treat. 2011;128:817–25.PubMedCrossRef

38.

Nagata C, Mizoue T, Tanaka K, Tsuji I, Wakai K, Inoue M, et al. Research group for the development and evaluation of cancer prevention strategies in Japan. Tobacco smoking and breast cancer risk: an evaluation based on a systematic review of epidemiological evidence among the Japanese population. Jpn J Clin Oncol. 2006;36:387–94.PubMedCrossRef

39.

Xue F, Michels KB. Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol. 2007;8:1088–100.PubMedCrossRef

40.

Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13:1141–51.PubMedCentralCrossRef

41.

Nagata C, Hu YH, Shimizu H. Effects of menstrual and reproductive factors on the risk of breast cancer: meta-analysis of the case-control studies in Japan. Jpn J Cancer Res. 1995;86:910–5.PubMedCrossRef

42.

Suzuki S, Kojima M, Tokudome S, Mori M, Sakauchi F, Fujino Y, Japan Collaborative Cohort Study Group, et al. Effect of physical activity on breast cancer risk: findings of the Japan collaborative cohort study. Cancer Epidemiol Biomarkers Prev. 2008;17:3396–401.PubMedCrossRef

43.

Suzuki R, Iwasaki M, Yamamoto S, Inoue M, Sasazuki S, Sawada N, Japan Public Health Center-based Prospective Study Group, et al. Leisure-time physical activity and breast cancer risk defined by estrogen and progesterone receptor status–the Japan public health center-based prospective study. Prev Med. 2011;52:227–33.PubMed

44.

Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer:a meta-analysis. Int J Cancer. 2007;121:856–62.PubMedCrossRef

45.

Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107:1608–17.PubMedCentralPubMedCrossRef

46.

Dong JY, Zhang L, He K, Qin LQ. Dairy consumption and risk of breast cancer:a meta-analysis of prospective cohort studies. Breast Cancer Res Treat. 2011;127:23–31.PubMedCrossRef

47.

Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Japan public health center-based prospective study on cancer cardiovascular diseases group. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 2003;95:906–13.PubMedCrossRef

48.

Iwasaki M, Inoue M, Otani T, Sasazuki S, Kurahashi N, Miura T, Japan Public Health Center-Based Prospective Study Group, et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan public health center-based prospective study group. J Clin Oncol. 2008;26:1677–83.PubMedCrossRef

49.

Nishio K, Niwa Y, Toyoshima H, Tamakoshi K, Kondo T, Yatsuya H, et al. Consumption of soy foods and the risk of breast cancer: findings from the Japan Collaborative Cohort (JACC) Study. Cancer Causes Control. 2007;18:801–8.PubMedCrossRef

50.

Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst. 2006;98:459–71.PubMedCrossRef

51.

Bosetti C, Scotti L, Negri E, Talamini R, Levi F, Franceschi S, et al. Benign ovarian cysts and breast cancer risk. Int J Cancer. 2006;119:1679–82.PubMedCrossRef

52.

Knight JA, John EM, Milne RL, Dite GS, Balbuena R, Shi EJ, et al. An inverse association between ovarian cysts and breast cancer in the breast cancer family registry. Int J Cancer. 2006;118:197–202.PubMedCrossRef

53.

Knight JA, Lesosky M, Blackmore KM, Voigt LF, Holt VL, Bernstein L, et al. Ovarian cysts and breast cancer: results from the women’s contraceptive and reproductive experiences study. Breast Cancer Res Treat. 2008;109:157–64.PubMedCrossRef

54.

Talamini R, Franceschi S, Favero A, Negri E, Parazzini F, La Vecchia C. Selected medical conditions and risk of breast cancer. Br J Cancer. 1997;75:1699–703.PubMedCentralPubMedCrossRef

55.

Weiss HA, Brinton LA, Potischman NA, Brogan D, Coates RJ, Gammon MD, et al. Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol. 1999;28:816–23.PubMedCrossRef

56.

Miller MD, Marty MA, Broadwin R, Johnson KC, Salmon AG, Winder B, California Environmental Protection Agency, et al. The association between exposure to environmental tobacco smoke and breast cancer:a review by the california environmental protection agency. Prev Med. 2007;44:93–106.PubMedCrossRef

57.

Pirie K, Beral V, Peto R, Roddam A, Reeves G, Green J. Million Women Study Collaborators. Int J Epidemiol. 2008;37:1069–79.PubMedCrossRef

58.

Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156:635–48.PubMedCentralPubMedCrossRef

59.

Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc. 2006;81:1290–302.PubMedCrossRef

60.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives:collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–27.CrossRef

61.

Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2005;41:2023–32.PubMedCrossRef

62.

Schwartzbaum J, Ahlbom A, Feychting M. Cohort study of cancer risk among male and female shift workers. Scand J Work Environ Health. 2007;33:336–43.PubMedCrossRef

63.

Pronk A, Ji BT, Shu XO, Xue S, Yang G, Li HL, et al. Night-shift work and breast cancer risk in a cohort of Chinese women. Am J Epidemiol. 2010;171:953–9.PubMedCentralPubMedCrossRef

64.

Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.PubMedCrossRef

65.

Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541–8.PubMedCrossRef

66.

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300.PubMedCrossRef

67.

Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Raloxifene use for the heart (RUTH) trial investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.PubMedCrossRef

68.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, NCIC CTG MAP.3 Study Investigators, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91.PubMedCrossRef

69.

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.PubMedCentralPubMedCrossRef

70.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Genetic/familial high-risk assessment: breast and ovarian. ver1. 2013.

71.

Pijep A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C, GENEPSO, EMBRACE, HEBON, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations:retrospective cohort study (GENE-RAD-RISK). BMJ. 2012;345:e5660.CrossRef

72.

Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, American Cancer Society Breast Cancer Advisory Group, et al. American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89.PubMedCrossRef

73.

Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, König R, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28:1450–7.PubMedCrossRef

74.

Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22:1055–62.PubMedCrossRef

75.

Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:159–64.PubMedCrossRef

76.

Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–75.PubMedCentralPubMedCrossRef

77.

King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, National Surgical Adjuvant Breast and Bowel Project, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. JAMA. 2001;286:2251–6.PubMedCrossRef

78.

Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80–7.PubMedCentralPubMedCrossRef

79.

80.

Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer. 2007;96:1335–42.PubMedCentralPubMed

81.

Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123:627–35.PubMedCrossRef

82.

Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28:3411–5.PubMedCrossRef

83.

Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29:2653–9.PubMedCrossRef

84.

Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005;23:1370–8.PubMedCrossRef

85.

Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol. 1990;8:1327–34.PubMed

86.

Ibrahim EM, Al-Homaidh A. Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies. Med Oncol. 2011;28:753–65.PubMedCrossRef

87.

Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:815–40.PubMedCentralPubMedCrossRef

88.

Holmes MD, Murin S, Chen WY, Kroenke CH, Spiegelman D, Colditz GA. Smoking and survival after breast cancer diagnosis. Int J Cancer. 2007;120:2672–7.PubMedCrossRef

89.

Dong JY, Qin LQ. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat. 2011;125:315–23.PubMedCrossRef

90.

Nechuta SJ, Caan BJ, Chen WY, Lu W, Chen Z, Kwan ML, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. 2012;96:123–32.PubMedCentralPubMedCrossRef

Title: The Japanese Breast Cancer Society clinical practice guideline for epidemiology and prevention of breast cancer
Authors: Naruto Taira
Masami Arai
Masahiko Ikeda
Motoki Iwasaki
Hitoshi Okamura
Kiyoshi Takamatsu
Seiichiro Yamamoto
Shozo Ohsumi
Hirofumi Mukai
Publication date: 01-01-2015
Publisher: Springer Japan
Published in: Breast Cancer / Issue 1/2015
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-014-0555-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2015

A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid

The Japanese Breast Cancer Society Clinical Practice Guideline for pathological diagnosis of breast cancer

Nipple reconstruction with banked costal cartilage after vertical-type skin-sparing mastectomy and deep inferior epigastric artery perforator flap

The Japanese Breast Cancer Society clinical practice guideline for radiotherapy of breast cancer

Early removal of drains and the incidence of seroma after breast surgery

Focal breast edema associated with malignancy on T2-weighted images of breast MRI: peritumoral edema, prepectoral edema, and subcutaneous edema

Keynote webinar | Spotlight on antibody–drug conjugates in cancer